Effect of dorzolamide/timolol combination on the visual field in glaucoma

References

• Collaborative Normal-Tension Glaucoma Study GroupThe effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucomaAm J Ophthalmol199812644985059780094
   PubMed Web of Science ®Google Scholar
• The AGIS InvestigatorsThe Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deteriorationAm J Ophthalmol2000130442944011024415
   PubMed Web of Science ®Google Scholar
• DranceSAndersonDRSchulzerMCollaborative Normal-Tension Glaucoma Study GroupRisk factors for progression of visual field abnormalities in normal-tension glaucomaAm J Ophthalmol2001131669970811384564
   PubMed Web of Science ®Google Scholar
• KassMAHeuerDKHigginbothamEJThe Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucomaArch Ophthalmol20021206701713 discussion 829–83012049574
   PubMed Web of Science ®Google Scholar
• AGIS InvestigatorsThe Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucomaAm J Ophthalmol2002134449951212383806
   PubMed Web of Science ®Google Scholar
• LeskeMCHeijlAHymanLBengtssonBDongLYangZEMGT GroupPredictors of long-term progression in the early manifest glaucoma trialOphthalmology2007114111965197217628686
   PubMed Web of Science ®Google Scholar
• GordonMOTorriVMigliorSEuropean Glaucoma Prevention Study GroupValidated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertensionOphthalmology20071141101917095090
   PubMed Web of Science ®Google Scholar
• LeskeMCHeijlAHusseinMBengtssonBHymanLKomaroffEEarly Manifest Glaucoma Trial GroupFactors for glaucoma progression and the effect of treatment: the early manifest glaucoma trialArch Ophthalmol20031211485612523884
   PubMedGoogle Scholar
• GordonMOBeiserJABrandtJDThe Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucomaArch Ophthalmol20021206714720 discussion 829–83012049575
   PubMedGoogle Scholar
• European Glaucoma SocietyTerminology and guidelines for glaucoma3rd edSavona, ItalyEuropean Glaucoma Society2008 Available from: http://www.eugs.org/eng/EGS_guidelines.aspAccessed August 15, 2014
   Google Scholar
• RossiGCPasinettiGMSandoloFBordinMBianchiPEFrom dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month, multicenter, open-label tolerability switch studyExpert Opin Pharmacother201112162425243121679090
   PubMed Web of Science ®Google Scholar
• SyedMFLoucksEKUpdate and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertensionClin Ophthalmol201151291129621966204
   PubMedGoogle Scholar
• KonstasAGBányaiLBlaskKDIntraocular pressure and safety in glaucoma patients switching to latanoprost/timolol maleate fixed combination from mono- and adjunctive therapiesJ Ocul Pharmacol Ther200420537538215650512
   PubMed Web of Science ®Google Scholar
• SontySHenryJCSharpeEDSuccess rates for switching to dorzolamide/timolol fixed combination in timolol responders who are insufficiently controlled by latanoprost monotherapyActa Ophthalmol (Copenh)2008864419423
   Web of Science ®Google Scholar
• MizoguchiTOzakiMWakiyamaHOginoNAdditive intraocular pressure-lowering effect of dorzolamide 1%/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucomaClin Ophthalmol201151515152022069355
   PubMedGoogle Scholar
• NixonDRYanDBChartrandJPPiemontesiRLSimonyiSHollanderDAThree-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapyCurr Med Res Opin20092571645165319476406
   PubMed Web of Science ®Google Scholar
• HommerAKimmichFSwitching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprostClin Ophthalmol2011562363121629567
   PubMedGoogle Scholar
• LeskeMCHeijlAHymanLBengtssonBEarly Manifest Glaucoma Trial: design and baseline dataOphthalmology1999106112144215310571351
   PubMed Web of Science ®Google Scholar
• BengtssonBLeskeMCHymanLHeijlAEarly Manifest Glaucoma Trial GroupFluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trialOphthalmology2007114220520917097736
   PubMed Web of Science ®Google Scholar
• KosekiNAraieMYamagamiJShiratoSYamamotoSEffects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressureJ Glaucoma19998211712310209728
   PubMed Web of Science ®Google Scholar
• FukuchiTYoshinoTSawadaHThe relationship between the mean deviation slope and follow-up intraocular pressure in open-angle glaucoma patientsJ Glaucoma201322968969723722866
   PubMed Web of Science ®Google Scholar
• JanulevicienëIHarrisAKagemannLSieskyBMcCranorLA comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patientsActa Ophthalmol Scand200482673073715606472
   PubMedGoogle Scholar
• MarenTHCarbonic anhydrase: general perspectives and advances in glaucoma researchDrug Dev Res1987104255276
   Web of Science ®Google Scholar
• RassamSMPatelVKohnerEMThe effect of acetazolamide on the retinal circulationEye (Lond)19937Pt 56977028287997
   PubMed Web of Science ®Google Scholar
• HarrisAArendOKagemannLGarrettMChungHSMartinBDorzolamide, visual function and ocular hemodynamics in normal-tension glaucomaJ Ocul Pharmacol Ther199915318919710385127
   PubMed Web of Science ®Google Scholar
• HarrisAJonescu-CuypersCPKagemannLEffect of dorzolamide timolol combination versus timolol 0.5% on ocular bloodflow in patients with primary open-angle glaucomaAm J Ophthalmol2001132449049511589868
   PubMed Web of Science ®Google Scholar
• QuarantaLMigliorSFlorianiIPizzolanteTKonstasAGEffects of the timolol-dorzolamide fixed combination and latanoprost on circadian diastolic ocular perfusion pressure in glaucomaInvest Ophthalmol Vis Sci200849104226423118502991
   PubMed Web of Science ®Google Scholar
• KruseWPatient compliance with drug treatment – new perspectives on an old problemClin Investig1992702163166
   Google Scholar
• NebbiosoMEvangelistaMLibrandoADi BlasioDPescosolidoNFixed topical combinations in glaucomatous patients and ocular discomfortExpert Opin Pharmacother201213131829183522770575
   PubMed Web of Science ®Google Scholar
• PescosolidoNParisiFRussoPBuompriscoGNebbiosoMRole of dopaminergic receptors in glaucomatous disease modulationBiomed Res Int2013201319304823878797
   PubMed Web of Science ®Google Scholar
• KonstasAGQuarantaLMikropoulosDGPeak intraocular pressure and glaucomatous progression in primary open-angle glaucomaJ Ocul Pharmacol Ther2012281263222004074
   PubMed Web of Science ®Google Scholar
• QuarantaLKatsanosARussoARivaI24-hour intraocular pressure and ocular perfusion pressure in glaucomaSurv Ophthalmol2013581264123217586
   PubMed Web of Science ®Google Scholar
• QuarantaLGandolfoFTuranoREffects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucomaInvest Ophthalmol Vis Sci20064772917292316799034
   PubMed Web of Science ®Google Scholar
• QuarantaLMigliorSFlorianiIPizzolanteTKonstasAGEffects of the timolol-dorzolamide fixed combination and latanoprost on circadian diastolic ocular perfusion pressure in glaucomaInvest Ophthalmol Vis Sci200849104226423118502991
   PubMed Web of Science ®Google Scholar
• DoughtyMJZamanMLHuman corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approachSurv Ophthalmol200044536740810734239
   PubMed Web of Science ®Google Scholar